Press Room Contact Us Career Opportunities
  ABOUT LCM   INSTITUTIONAL SALES & TRADING   RESEARCH   PRIME SERVICES   EVENT CALENDAR  
 
 

Lazard Capital Markets is a growth-oriented full service broker-dealer with a unique position in today's capital markets. 

Our Institutional clients value our focused, action-oriented proprietary research, which is based on deep domain expertise in the Healthcare, Consumer, Energy, Technology and Transportation sectors. 

Our Sales and Trading professionals have long-standing relationships with over 600 institutional accounts, and, with an average of 15 years of experience, have an intimate knowledge of our clients' investment objectives. Finally, our relationship with Lazard, an international investment bank, which operates in 39 cities across 21 countries, provides us with unparalleled global connections. 

The distinctive combination of our experience, focus, global reach, and thought leadership provides clients with an unparalleled resource: Lazard Capital Markets.


                                                                                                                                                                   
 
Acute Care Hospitals — thoughts on the “utilization trade”        DOD Budget Priorities statement — potential winners in our coverage        Lazard Capital Markets Daily Friday, January 27, 2012        PCLN: Raising 4Q, but 2012 down on FX; BUY        DLPH: Strong results and outlook; buyback should help diminish concerns of upcoming lockup expiration; BUY        CPHD: Significant strength in new system sales in 4Q11, but clinical reagent revenue falls short again; NEUTRAL        JNPR: Results in line with preannouncement; guidance lowered on challenging spending environment; NEUTRAL        SYNA: Facing macro headwinds in PCs but gaining share in mobile; NEUTRAL        VRSN: 4Q results mixed but margin story continues; lack of near-term catalysts leaves us NEUTRAL        RVBD: Blows a tire with weak March quarter outlook but still expecting strong 2012; BUY        WWW: 4Q preview and thoughts on potential transformative acquisition of PSS assets; NEUTRAL        AMGN: 4Q11 results; Micromet acquisition gives company BiTE technology platform; NEUTRAL        AOS: First Take; strong 4Q 11; 2012 guidance looks conservative; BUY        MRVL: HDD still causing issues but this is likely the bottom; BUY        What to look for this weekend at AATS/STS – mainly THVs, but also LVADs, and EVAR; should be a positive for EW        IMGN: Reports FY2Q12; T-DM1’s EMILIA Phase 3 data and Roche’s adjuvant strategy are key drivers in 1H12; NEUTRAL       
 
  Business Continuity Plan   Terms and Conditions of Use   Member FINRA / SIPC